some Echinacea preparations can probably help prevent and treat the common cold. However, there is not enough evidence to support a particular product or type of preparation.
B A C K G R O U N D
Extracts of the plant Echinacea (family Compositae) are widely used by patients and practitioners in some European countries (for example the Netherlands and Germany) and in the USA for preventing and treating upper respiratory tract infections. On the German market there are at present more than 200 preparations obtainable which contain extracts of Echinacea alone or in combination with other plant extracts. In 1993 for the five leading preparations in Germany prescriptions of over 3 million daily doses with a cost of 50 million DM (about $ 35 million) were registered (Haustein 1994) . Although the prescription of extracts of Echinacea by physicians has decreased in the last years (for example from 1992 to 1993 between 21 and 35% for the five market leading preparations (Haustein 1994) ), this has probably at least in part been compensated for by an increase of over-the-counter use.
Extracts of Echinacea contain varying concentrations of flavonoids, essential oils, polysaccharides, derivates of caffeic acid, polyacetylenes, alkylamides and alkaloids. The stimulation of non-specific immune defence capacities, such as phagocytosis of polymorphonuclear neutrophile granulocytes, has been postulated as the mechanism of action (Bauer 1990) .
Despite its widespread use, there is considerable debate about the effectiveness of Echinacea, and doubts have been raised about safety in the (relatively rare) case of parenteral (intravenous or intramuscular) application (Schönhöfer 1989 , Bauer 1996 .
The assessment of effectiveness is complicated by the limited comparability of the available preparations for the following reasons: 1) Three different species are in medical use: Echinacea (E.) purpurea, E. pallida, and E. angustifolia. 2) Different parts of the plant are used (roots, herbs, whole plant).
3) Different methods of extraction are used. 4) In some preparations other plant extracts or homeopathic components are added.
O B J E C T I V E S
In 1994 our group published a systematic review of the available controlled clinical trials (also including non-randomized trials) investigating preparations containing extracts of Echinacea in a variety of conditions (Melchart 1995a). Our objective now was to perform a more detailed review focussing on the assessment of the available evidence from randomized clinical trials investigating the effectiveness of Echinacea extracts for the prevention and the treatment of the common cold.
C R I T E R I A F O R C O N S I D E R I N G S T U D I E S F O R T H I S R E V I E W

Types of studies
Prospective clinical trials with random or quasi-random (such as alternation, date of birth etc.) allocation to treatment and control groups.
Types of participants
Studies were included if participants were -patients with unspecific viral upper respiratory tract infections (URTI; clinical diagnoses: common cold, influenza-like syndrome, viral URTI -it was not possible to apply a standard definition of common cold across all trials) -volunteers without acute upper respiratory tract infections but treated for preventative purposes (prevention studies). Studies on patients suffering from other upper respiratory tract infections with a defined etiology (e.g. influenza) or a more specific symptomatology (acute sinusitis, angina tonsillaris) were not included.
Types of intervention
Treatment group: Application of preparations containing extracts of Echinacea either as the only component (mono-preparations) or in combination with other plant extracts. Control group: Other strategies (other therapy, no treatment, placebo)
Types of outcome measures
To be included in the overview trials must include clinical outcome measures related to occurrence (prevention studies), severity or duration (treatment studies) of infections. Trials focussing solely on physiological parameters (such as phagocytosis activity etc.) were excluded.
S E A R C H S T R A T E G Y F O R I D E N T I F I C A T I O N O F S T U D I E S
See: search strategy
The following sources were searched: 1) MEDLINE 1966 to 1998: all hits for Echinac* screened. 2) EMBASE 1991 to 1998: all hits for Echinac* screened.
3) Database of the Cochrane Acute Respiratory Infections Group: all hits for Echinac* screened. 4) Database of the Cochrane Field Complementary Medicine: all hits for Echinac* screened. 5) Database Phytodok (Munich, specialized on Phytomedicine) screening all clinical studies for Echinac*. 6) Bibliographies of identified articles 7) Existing reviews 8) Manufacturers and researchers in the field were contacted and explored for published and unpublished trials. 9) Proceedings of phytomedicine congresses (International Congresses on Phytomedicine and Congresses of the German Society of Phytotherapy) were screened.
M E T H O D S O F T H E R E V I E W
Study identification: Titles and -if available -abstracts of all references identified were screened by one reviewer (K.L.) who sorted out all which did not report on trials in humans including a control group. Copies of all other references were obtained and checked further for eligibility.
Assessing eligibility: All identified controlled studies testing an Echinacea preparation in humans were checked for fulfillment of the selection criteria by three independent reviewers. Basic information (preparation tested, subjects included, type of control, design, reason for exclusion) of the trials excluded at that step was extracted. A total of 40 studies were assessed. There were four disagreements among the reviewers concerning eligibility; three were due to reading errors and could be easily resolved in discussion. The fourth was about a trial which did not state the method of allocation to treatment groups (Kleinschmidt 1965) ; as the description of this trial made it seem likely that allocation was quasi-randomized (alternation) it was finally decided to include this study.
Data extraction:
Descriptive information on patients, interventions, outcomes, results, drop-outs, and side effects was extracted by at least two independent reviewers using a standard form. Authors/manufacturers were contacted and asked to provide lacking and/or additional data. However, while we obtained some useful information regarding the general methods of some trials, lacking details (such as standard deviations, exact n for specific comparisons etc.) on results could not be collected with one exception (mostly because the trials were rather old and the data no longer fully available). Details of the included studies are described in the table of included studies. The following abbreviations are used in the table: comb = combination; E.pur = Echinacea purpurea, E.pal = Echinacea pallida, E.ang = Echinacea angustifolia -Methods (abbreviation A: method of allocation to groups; C: method of concealment of allocation; B: blinding; S: selection bias after allocation; Q: results of the quality scoring using the Jadad scale and our IV scale); -Participants (N: number of patients randomized/analysed; P: condition/participants; D: demographic information; S: trial setting) -Interventions (T: treatment group; C: control group); -Outcomes (type and timing of outcomes); -Notes: descriptive summary of results and remarks.
Assessment of quality of reports/methodological quality: The quality of reports/methodological quality of included trials was assessed by at least two independent reviewers using -the method by Jadad et al. (Jadad 1996) (items on random allocation, blinding and reporting of drop-outs/exclusions adding to a summary score of 0 to 5 points); -a scoring method developed by ourselves and used in published (Linde 1996a , Linde 1996b and ongoing systematic reviews, the internal validity scale (IV scale). This instrument has 6 items (allocation to groups, concealment of allocation, baseline comparability, blinding of patients, blinding of evaluators, and likelihood of selection bias after allocation to groups by dropout, etc.). Each item is scored between 0 (= criterion not met or insufficient information) and 1 (criterion met). The assessment of randomization concealment and double-blinding in this score system is equivalent to the method used by Schulz et al. (Schulz 1995) . For the calculation of scores only the information provided in the publications or written reports was used. The resulting quality scores are given in the table of included studies. For the informal description of quality features in that table we also used additional information gathered in personal communication from authors and sponsors.
Summarizing results:
We had decided in advance that a quantitative meta-analysis should be performed only under the following preconditions: -preparations are comparable (from the same parts (e.g. roots) of the same plant species (e.g. E. purpurea) extracted in a similar way (e.g. ethanolic extraction)) -patients are comparable (similar definition of common cold/influenza-like syndromes) -the methodology is similar (quality issues and outcome measurement). Predefined main outcome measure for prevention trials was the number of patients with at least one episode of infection (results expressed as relative risk = proportion of patients with infection in the experimental group/proportion of patients with infection in the control group). Predefined outcome measures for treatment trials were duration and severity of infection.
Due to the heterogeneity of trials and insufficient reporting the summarizing of results proved to be difficult. For the prevention studies we could extract data on numbers of participants with at least one infection. As the studied test preparations differed between the placebo-controlled trials we refrained from calculating a pooled effect size estimate. For a set of three studies comparing a combination of Echinacea with other plant extracts and no treatment, the above-mentioned preconditions were met. For the studies comparing Echinacea preparations and placebo in the treatment of common colds the preconditions were not met.
D E S C R I P T I O N O F S T U D I E S
A total of 40 trials of preparations of Echinacea alone or in combinations with other plant extracts with a parallel control group were identified. 14 fully met the criteria for inclusion. One study made no explicit statement about the method of allocation to treatments; as this study was likely to have used alternation it was included (Kleinschmidt 1965) . One study also investigated patients with suspected bacterial infection; as the majority of patients had a viral infection, however, and the results were presented separately for patients with suspected viral and bacterial infections, the trial was included (Bräunig 1993) . The 16 included studies (involving 3396 patients) are summarized in the table of included studies. The remaining 24 studies did not meet the inclusion criteria (most often the reason for exclusion was either an indication other than common cold or non-random allocation; see table of excluded studies for details).
Based on clinical aspects we divided the 16 included studies into three categories: -prevention trials with a placebo control (five trials with 1272 patients); -prevention trials with a no treatment comparison (three trials with 1139 patients); -treatment trials with a placebo control (eight trials with 985 patients). Apart from two studies (Scaglione 1995 , Hoheisel 1997 all were performed in Germany. Not a single trial was published in a Medline-listed journal.
Prevention trials with a placebo comparison
The five trials (Forth 1981 , Hoheisel 1997 , Melchart 1998 , Schmidt 1990 , Schöneberger 1992 in this category investigated a total of five different preparations in seven treatment groups (two trials -Forth 1981, and Melchart 1998 -were three-armed); two of the preparations were combinations and three were monopreparations (E. purpurea herb, E. purpurea roots, E. angustifolia roots). In four of the trials participants took the study medication over a longer period (eight to 12 weeks) and the primary outcome measure was the number of patients with at least one infection. The remaining trial (Hoheisel 1997) differed considerably from the other four and has to be considered as a mixture of prevention and treatment trial. Workers in a furniture factory with a history of recurrent upper respiratory tract infection were asked to contact the factory physician in case of any first symptoms or feelings that they might be getting a cold. They then received either E. purpurea herb or placebo. Primary outcome measures were the number of patients developing a "full common cold" and the duration of illness.
Prevention trials with a no treatment comparison
In this category there are three relatively large trials (number of participants 209, 284 and 644) testing all a combination of Echinacea angustifolia and pallida roots, Baptisia tinctoria roots, Thuja occidentalis herb, and several homeopathic dilutions. The trials have been published 1961 (Helbig 1961 ), 1965 (Kleinschmidt 1965 ), and 1974 (Freyer 1974 . All included children who were referred either to a pediatric in-patient department (for a variety of reasons, Helbig 1961) or for a stay in a health resort.
Treatment trials with a placebo control
The eight trials in this category investigated three different combinations and two mono-preparations. Inclusion diagnoses were "common cold" or "acute viral upper respiratory tract infection" in five trials, and more globally "upper respiratory tract infection" in three. While in two of these the description suggested that patients suffered from common colds, in one trial (Bräunig 1993) patients were classified according to suspected viral and bacterial origin. Treatment periods varied between six and ten days (as far as there was clear information). In most trials there seemed to be no predefined main outcome measures. Most frequently a catalogue of symptoms was scored at two control visits.
M E T H O D O L O G I C A L Q U A L I T Y
Prevention trials with a placebo comparison
Apart from one study with severe methodological flaws (Forth 1981; an unclear, but probably large number of patients have not been followed up and were excluded from the analysis) the studies in this category have acceptable methodological quality. All are randomized and double-blind, and major selection bias after allocation is unlikely. Fundamental problems of all trials are (1) the definition of common cold/upper respiratory tract infection and the reliability and validity of the clinical assessments made; and (2) limited sample size.
Prevention trials with no treatment controls
The three trials in this category cannot be considered to meet modern standards of good methodological quality. Allocation to the groups has not been truly randomized (alternate allocation explicitly described in Helbig 1961 and Freyer 1974 , likely in Kleinschmidt 1965 and there was no blinding. In all three trials the operationalization of outcome measurement (definition of endpoints) was completely unclear. While there were no explicit descriptions of drop-outs and withdrawals the study approaches and conditions make it rather unlikely that there was a relevant loss to follow up.
3. Treatment trials with a placebo control All eight trials in this category were randomized, and in all, apart from one trial which was single blind (Scaglione 1995) , an attempt was made at double-blinding. In one three-armed study (Bräunig 1992a) comparing two different dosages of an Echinacea purpurea root extract and placebo, however, there is a severe flaw. All placebo patients received the low dosage; the high-dose group can, therefore, not be considered to be truly blind. Only one had a single clearly predefined main outcome measure.
Overall, the quality of reporting of most studies was insufficient. As a consequence, a reliable and valid assessment of the methodological quality of the trials was difficult. Some (Forth 1981 , Freyer 1974 , Helbig 1961 , Kleinschmidt 1965 , Bräunig 1992a ) of the trials have severe shortcomings, and in some other reservations seem justified. Especially in the prevention trials where the medications have been taken over longer periods, it cannot be excluded that some unblinding might have happened as Echinacea extracts have a very characteristic taste. The method to conceal allocation has been described only in two study reports; for a number of other studies we could get information from authors or sponsors that neutrally packaged, consecutively numbered drugs were used. Drop-outs and withdrawals were described well in three trials only; in a number of reports the description suggested that there were no drop-outs or withdrawals but explicit statements were lacking. An intent to treat analysis was performed in three trials.
R E S U L T S
Prevention trials with a placebo comparison
Due to the heterogeneity of the five trials in this category, the calculation of a pooled effect size seemed not adequate. Two of the five trials (Forth 1981 , Hoheisel 1997 found a statistically significant lower incidence of infection in the treatment group (rate ratios 0.51 and 0.67) while in the other trials there were only trends in favour of the treatment groups (rate ratios 0.84, 0.86, 0.88). Results on severity and duration of infections were reported in three trials. There were no clear trends favouring the treatment or the placebo group regarding the severity of occurring infections. One trial (Hoheisel 1997) found that the duration of illness was significantly shorter in the treatment group while in the two other trials (Melchart 1998 , Schöneberger 1992 there were no marked differences. The number of patients reporting adverse effects were given in four trials (none in both groups in the trial by Hoheisel 1997; 18 of 100 patients in the E. angustifolia group, 10 of 99 in the E. purpurea group, and 11 of 90 in the placebo group in Melchart 1998; 12 of 322 in the treatment group and 10 of 324 in the placebo group in Melchart 1998; 7 of 54 in the treatment group and 11 of 54 in the placebo group in Schöneberger 1992).
Prevention trials with no treatment controls
In all three trials the number of children with infection was significantly lower in the group receiving the Echinacea combination compared to the no treatment group. The pooled rate ratio was 0.58 (0.42 to 0.81). There was no extractable data on other outcomes or side effects.
3. Treatment trials with a placebo control Due to the insufficient presentation of results and the heterogeneity of outcome measures, data for a quantitative analysis could be extracted from only two trials for duration of illness, three trials for running nose, and from five trials (with a total of six treatment groups as one trial tested two dosages) when either duration, running nose or a summary symptom score was used (see analyses). The heterogeneity of the tested preparations precluded a pooled analysis. Overall, six trials claimed significantly positive results for the tested preparations over placebo (Bräunig 1992a for the high dose tested, Bräunig 1993 , Reitz 1990 , Scaglione 1995 , Vorberg 1984 , Vorberg 1989 , one found significant results for a subgroup only (Henneicke 1997), and two trials found no difference after treatment (Bräunig 1992a for the low dose tested, and Dorn 1989; in this trial, however, patients in the treatment group had more severe symptoms at baseline). Only three trials provided information on adverse events. In two (Dorn 1989 , Scaglione 1995 there were no adverse effects and in one (Reitz 1990) four patients in the treatment group and five in the placebo group reported adverse effects.
D I S C U S S I O N
The 16 controlled trials summarized in this review suggest that preparations containing extract of Echinacea probably can be effective in the prevention and treatment of common colds. Still, the evidence is far from compelling and conclusive for clinical decision making. The biggest problem is the great heterogeneity and the unclear comparability of the investigated products. A second relevant problem is that the quality of reporting is insufficient in about two thirds of the trials and raises doubts about the rigour. If the analyses were restricted to any single preparation or extract, it was not possible to perform conclusive quantitative meta-analyses.
The assessment of the evidence is further complicated by the fact that probably not all possibly relevant trials on the topic have been published. Until recently, herbal preparations have been assessed in Germany by a special commission (Commission E) at the Federal Drug Institute. This commission has licensed Echinacea purpurea herb and Echinacea pallida root while the evidence was judged as insufficient for other extracts (Dorsch 1996 ,Blumenthal 1998 . The database on which the decisions are made is not fully transparent; it might be that positive studies exist which are not published for reasons of competition. We have personal information that a number (between five and ten) of unpublished trials of Echinacea preparations (at least partly on common cold) exist, probably in the majority with "negative" results.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
While overall there is some positive evidence, few recommendations can be made regarding the use of Echinacea products in practice. The heterogeneity of the available preparations and the limited quality and consistency of the evidence do not allow clear conclusions about which product might be effective in what dose and in what circumstances. Patients and health care providers who want to use preparations containing extracts of Echinacea should be aware of the possible extreme differences in the chemical composition and that there is no solid base of evidence concerning their efficacy. Cases of allergic reactions have been reported after parenteral use of Echinacea products (Schönhöfer 1989 , Bauer 1996 . As there is no evidence from controlled clinical trials that such parenteral administration is beneficial in the treatment and prevention of uncomplicated upper respiratory tract infections it should be discouraged. For oral intake the risks of serious adverse effects seem very small.
Implications for research
Given the widespread use of Echinacea products further research is clearly desirable. The use of chemically well-defined preparations is a precondition for the assessment of the comparability of results from different studies. There is ample space for improvement in the methodology and the reporting of clinical trials. The diagnostic classification of upper respiratory tract infections has to be more clearly defined in future studies. A single main outcome measure should be predefined for the confirmatory statistical analysis. The clinical assessment of the common cold is not easy; documentation instruments must not be too complicated (to warrant feasibility) but still should cover the relevant aspects of the course of the disease.
The available prevention studies suggest that any eventual prophylactic effect of Echinacea preparations might be relatively moderate in size (around 15 to 20% relative risk reduction). Studies to detect such differences have to have large sample sizes and are costly. At least in Germany, where most of the available studies have been performed, it seems questionable if such studies will be done. Most manufacturers of Echinacea products are relatively small and have only limited research expertise and budgets. As plant extracts cannot be patented easily the results of studies can be used by anyone else and do not provide marketing advantages.
In self-medication many people take Echinacea products when they experience the very first symptoms of a common cold and clearly before the illness has reached its maximum. Dosage is very high in the beginning and reduced after one or two days. This strategy is not easy to investigate in a normal general practice setting where patients seek doctor's help only when the symptoms become burdening. The only study investigating this approach (Hoheisel 1997) yielded clearly positive results. In another recent study in which patients with a common cold were treated only the subgroup with recent onset of symptoms seemed to have a relevant benefit (Henneicke 1997). The treatment of early illness should therefore be preferred for research.
The informal information we got on publication bias is a major reason of concern. As long it is not guaranteed that all trials of Echinacea products will be published a question mark will remain on findings in systematic reviews on this topic.
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External sources of support
• Karl und Veronica Carstens Foundation GERMANY Interventions T: combination 2 (Resistan containing mother tinctures of Echinacea angustifolia, Eupatorium perfoliatum, and Baptisia tinctoria) 30 ml on the first two days and 15 ml for the next four days C: placebo Outcomes Symptoms (tiredness, myalgia, headaches, running nose, cough, sore throat; assessed after two to four and six to eight days) Notes Results (more reduction in the treatment group but no significant differences in symptom severity at the end of the study) difficult to interpret due to significant differences in the baseline severity of symptoms (more severe in the treatment group). , para. 6.1, that "the German drug regulatory authority recommends that it be used for no longer than eight weeks at a time". I have asked the Consumer Network about the evidence for this and been told that it is not available. Nevertheless, I think that if it is indeed a recommendation of the German drug regulatory authority, it should be mentioned in both the review and the abstract.
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